CHARLES RIVER LABORATORIES INTERNA (CRL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CRL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CRL | Non-Executive Chair | 70 | ["Co-founder of Rallybio Corporation", "Former Chief Executive Officer (2018-2023)", "Former Executive Chair (2023-2024)", "Global Head of Research & Development at Alexion Pharmaceuticals, Inc.", "President of R&D at AstraZeneca PLC", "Director of Novo Nordisk and SpringWorks Therapeutics", "Director of 5:01 Acquisition Corp."] | [] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Mackay is co-founder, former Chief Executive Officer (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and, from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay previously served on the boards of Novo Nordisk and SpringWorks Therapeutics. From October 2020 through April 2022, Dr. Mackay served as a director of 5:01 Acquisition Corp. Dr. Mackay has been a director of the Company since July 2017. Dr. Mackay s extensive experience leading research and development organizations at both global pharmaceutical and biotechnology companies provides us with a unique combination of expertise.